Search

Your search keyword '"F. Sperandi"' showing total 8 results
Start Over Author "F. Sperandi" Topic nivolumab
8 results on '"F. Sperandi"'

1. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.

Author

Gelsomino F, Di Federico A, Filippini DM, Dall'Olio FG, Lamberti G, Sperandi F, Balacchi C, Brocchi S, and Ardizzoni A

Subjects
Aged, Antineoplastic Agents, Immunological pharmacology, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms immunology, Lung Neoplasms metabolism, Lung Neoplasms pathology, Prognosis, Antibodies, Monoclonal, Humanized therapeutic use, B7-H1 Antigen antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung drug therapy, Drug Resistance, Neoplasm drug effects, Immune Checkpoint Inhibitors therapeutic use, Nivolumab pharmacology, Programmed Cell Death 1 Receptor antagonists & inhibitors
Published
2020
Full Text
View/download PDF

2. Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

Author

Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, and Delmonte A

Subjects
Adult, Aged, Blood-Brain Barrier drug effects, Brain Neoplasms pathology, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung epidemiology, Carcinoma, Non-Small-Cell Lung pathology, Central Nervous System Neoplasms pathology, Central Nervous System Neoplasms secondary, Cohort Studies, Female, Humans, Italy epidemiology, Male, Middle Aged, Neoplasm Staging, Brain Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Central Nervous System Neoplasms drug therapy, Nivolumab administration & dosage
Abstract

Background/aim: Brain metastases are an additional challenge in patients with non-small-cell lung cancer (NSCLC) because most chemotherapy agents cannot cross the blood-brain barrier. Nivolumab has demonstrated efficacy in patients with advanced squamous NSCLC, but because patients with central nervous system (CNS) metastases are typically excluded from registration trials, 'field-practice' data are needed., Patients and Methods: Patients in the Italian cohort of the Expanded Access Program (EAP) who had CNS metastases at baseline were analyzed., Results: Thirty-seven patients with CNS metastases received a median of six doses of nivolumab. Three patients (8%) had grade 3-4 adverse events and one patient discontinued due to an adverse event. The objective response rate was 19%. Median overall survival was 5.8 (95% confidence interval=1.9-9.8) months and median progression-free survival was 4.9 (95% confidence interval=2.7-7.1) months., Conclusion: The safety and efficacy of nivolumab in patients with CNS metastases appear to be similar to those seen in the overall EAP cohort in Italy., (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2019
Full Text
View/download PDF

3. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.

Author

Dall'Olio FG, Sperandi F, Rihawi K, Gargiulo M, Melotti B, Brocchi S, Gelsomino F, and Ardizzoni A

Subjects
Arterial Occlusive Diseases diagnosis, Carcinoma, Squamous Cell secondary, Humans, Lung Neoplasms pathology, Male, Prognosis, Antineoplastic Agents, Immunological adverse effects, Arterial Occlusive Diseases chemically induced, Carcinoma, Squamous Cell drug therapy, Lung Neoplasms drug therapy, Nivolumab adverse effects, Programmed Cell Death 1 Receptor antagonists & inhibitors
Published
2018
Full Text
View/download PDF

4. Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

Author

Dall'Olio FG, Brocchi S, Massucci M, Sperandi F, Melotti B, and Ardizzoni A

Subjects
Biomarkers, Tumor, Cryptogenic Organizing Pneumonia, Disease Progression, Humans, Lung Neoplasms, Pneumonia, Programmed Cell Death 1 Receptor, Carcinoma, Non-Small-Cell Lung, Nivolumab
Published
2018
Full Text
View/download PDF

5. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

Author

Gelsomino F, Fiorentino M, Zompatori M, Poerio A, Melotti B, Sperandi F, Gargiulo M, Borghi C, and Ardizzoni A

Subjects
Atherosclerosis immunology, Atherosclerosis pathology, Humans, Plaque, Atherosclerotic immunology, Plaque, Atherosclerotic pathology, Programmed Cell Death 1 Receptor immunology, Atherosclerosis drug therapy, Nivolumab therapeutic use, Plaque, Atherosclerotic drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors
Published
2018
Full Text
View/download PDF

7. 'Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.'

Author

Francesca Sperandi, Paola Antonelli, Diana Giannarelli, Filippo de Marinis, Silvia Quadrini, Paolo Bidoli, Daniele Turci, Milena Vitali, Luana Calabrò, Irene Prediletto, Anna Manzo, Angelo Delmonte, Marcello Tiseo, Lucio Crinò, Gabriele Minuti, Hector Soto Parra, Fabiana Vitiello, Francesco Grossi, Domenico Galetta, Simone Scagnoli, and Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Sperandi F, Vitiello F, Vitali M, Soto Parra HJ, Scagnoli S, Minuti G, Calabrò L, Tiseo M, Turci D, Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Pediatrics, business.industry, Immune checkpoint inhibitors, respiratory tract diseases, 03 medical and health sciences, 0302 clinical medicine, Survival benefit, 030220 oncology & carcinogenesis, Expanded access, Internal medicine, Cohort, medicine, Squamous non-small cell lung cancer, Nivolumab, business, Nivolumab, non small cell lung cancer, immunotherapy, expanded access program, 030215 immunology
Abstract

3067Background: Nivolumab is the first checkpoint inhibitor approved for the treatment of squamous non small cell lung cancer (Sq-NSCLC) to show a survival benefit in a randomised phase III trial. ...

Published
2016

8. Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population

Author

Simone Scagnoli, P. Bidoli, Daniele Turci, F. De Marinis, Paola Antonelli, H. Soto Parra, Gabriele Minuti, Silvia Quadrini, I. Prediletto, Domenico Galetta, Francesca Sperandi, Francovito Piantedosi, M. Tiseo, L. Crinò, Diana Giannarelli, Anna Manzo, Angelo Delmonte, Milena Vitali, Francesco Grossi, Luana Calabrò, and Crino’ L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Sperandi F, Piantedosi F, Vitali M, Soto Parra H, Scagnoli S, Minuti G, Calabro’ L, Tiseo M, Turci D, Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D.

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, Hematology, World population, Nivolumab, non small cell lung cancer, immunotherapy, NO, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, Nursing, 030220 oncology & carcinogenesis, Family medicine, Expanded access, Cohort, Medicine, Nivolumab, business
Published
2016

Catalog

Books, media, physical & digital resources
See catalog results